Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

SANICKA Inc
Profile last edited on: 2/27/2023      CAGE: 8WKJ8      UEI: N6X4B47G69J3

Business Identifier: Providing healthcare organizations with critical data to support patient-specific leukemia treatment
Year Founded
2021
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1835 Indiana Avenue Ne
Atlanta, GA 30307
   (404) 545-1972
   N/A
   www.sanicka.com
Location: Single
Congr. District: 05
County: DeKalb

Public Profile

SANICKA Inc. was incorporated in Georgia in 2021 and is based on patented inventions derived from the Biomedical Systems Engineering Laboratory at the Georgia Institute Technology and Emory University. SANICKA offers integrated in-vitro/in-silico/in-vivo technologies, providing innovative and tailor-made solutions to the Healthcare & Biopharma industries. The core competence of the firm team is mathematical modeling of biological systems.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$396,908
Phase II Dollars
$0
Total Awarded
$396,908

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $396,908
Project Title: A Precision Medicine Tool for Optimal Personalized Treatment in Patients with Acute Myeloid Leukemia

Key People / Management

  Sakis Mantalaris -- CEO

  Vincent La Terza

  Athanasios Mantalaris

  Nicki Panoskaltsis -- Medical Director

Company News

There are no news available.